More than 5000 attendees and 500 exhibitors took part in the DIA Annual Meeting this year, and more than 15,000 global attendees and 2,500 CEOs featured at the 2015 BIO Exhibition.
Anfisa Shakhova, Director of Business Development, Data Matrix, a spinoff of OCT company, participated in BIO and took part in the panel discussion: ”Reaching Out to Russia: The Biotech R&D Landscape and Global Drug Discovery Case Studies Emerging Opportunities in Global Markets”.
Emerging markets are becoming more attractive for biotech R&D. Attractions include the financing environment, a growing infrastructure with high-quality research facilities, experience in organization of clinical trials from early proof-of-concept phases to international multicenter studies, wider pools of patients and low levels of competition for investigators and new opportunities for collaborative projects and “mirroring” research that accelerate the development process. Among invited speakers were key leaders from venture capital funds and development institutes: Alexander Alexandrov, Medical Director Maxwell Biotech Group, Andrei Gudkov, CSO Incuron, Kirill Kaem, Vice-President and Executive Director of the BioMed. They discussed case studies and shared their experience, in order to explore opportunities and challenges in the biotech sector in Russia.
BIO international Convention is the leading biotech event gathering Life Science professionals from all around the world. The American Association BIO (Biotechnology Industry Organization) organizes every year an international congress on biotechnology. Over the years, this conference has become the worldwide not to be missed event. It allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies.
The BIO Exhibition host every year thousands of organizations including the leading biotech companies, top 25 pharma companies, top 20 CROs and CMOs, more than 300 academic institutions including the major research labs and government agencies and the leading consultants and service companies.
DIA is a global volunteer and member community representing thousands of life science professionals working together to bring innovative, safe and effective medical products to patients that will change the future of health care. An association of more than 30,000 key stakeholders, DIA, founded as the Drug Information Association (DIA), builds productive relationships by bringing together regulators, life sciences professionals, academics and researchers, patient advocates and other influencers involved in the development, discovery and life cycle management of biotechnology, pharmaceuticals, medical devices and related health care products to exchange knowledge and collaborate in a neutral setting.